NOTICES
HEALTH CARE COST CONTAINMENT COUNCIL
Mandated Benefits
[37 Pa.B. 6724]
[Saturday, December 15, 2007]Section 9 of act 14 of July 17, 2003 (P. L. 31, No. 14) (Act 14) requires that the Health Care Cost Containment Council (Council) review proposed mandated health benefits on request of the executive and legislative branches of government. The Council has been requested by Representative Anthony DeLuca, Chairperson of the House Insurance Committee, to review House Bill 1105, Printer's Number 1335 (Curry). House Bill 1105 would establish a standard of care so that patients with severe bleeding disorders can receive necessary and appropriate medical care. For patients with hemophilia and other bleeding disorders, the legislation would preserve access to the following services: medical services provided by the State-recognized hemophilia programs; the clinical laboratory services associated with the State-recognized programs; all blood clotting products approved by the U. S. Food and Drug Administration; full-service home care pharmacies and home support services; and mandatory medical screenings for bleeding disorders for women prior to undergoing certain surgical procedures.
The Council is requesting that anyone supporting or opposing these mandated insurance benefits provide six copies of the documentation to the Council no later than 5 p.m. on February 15, 2008. The documentation should be mailed to Charles Betley, Health Care Cost Containment Council, 225 Market Street, Suite 400, Harrisburg, PA 17101.
Documentation submitted should be in accordance with the following information categories described in section 9 of Act 14 of 2003:
(i) The extent to which the proposed benefit and the services it would provide are needed by, available to and utilized by the population of the Commonwealth.
(ii) The extent to which insurance coverage for the proposed benefit already exists, or if no coverage exists, the extent to which this lack of coverage results in inadequate health care or financial hardship for the population of the Commonwealth.
(iii) The demand for the proposed benefit from the public and the source and extent of opposition to mandating the benefit.
(iv) All relevant findings bearing on the social impact of the lack of the proposed benefit.
(v) Where the proposed benefit would mandate coverage of a particular therapy, the results of at least one professionally accepted, controlled trial comparing the medical consequences of the proposed therapy, alternative therapies and no therapy.
(vi) Where the proposed benefit would mandate coverage of an additional class of practitioners, the results of at least one professionally accepted, controlled trial comparing the medical results achieved by the additional class of practitioners and those practitioners already covered by benefits.
(vii) The results of any other relevant research.
(viii) Evidence of the financial impact of the proposed legislation, including at least:
(A) The extent to which the proposed benefit would increase or decrease cost for treatment or service.
(B) The extent to which similar mandated benefits in other States have affected charges, costs and payments for services.
(C) The extent to which the proposed benefit would increase the appropriate use of the treatment or service.
(D) The impact of the proposed benefit on administrative expenses of health care insurers.
(E) The impact of the proposed benefits on benefits costs of purchasers.
(F) The impact of the proposed benefits on the total cost of health care within the Commonwealth.
MARC P. VOLAVKA,
Executive Director
[Pa.B. Doc. No. 07-2324. Filed for public inspection December 14, 2007, 9:00 a.m.]
No part of the information on this site may be reproduced for profit or sold for profit.This material has been drawn directly from the official Pennsylvania Bulletin full text database. Due to the limitations of HTML or differences in display capabilities of different browsers, this version may differ slightly from the official printed version.
